What is Leerink Partnrs’ Estimate for VRDN FY2029 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDNFree Report) – Analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Viridian Therapeutics in a note issued to investors on Monday, January 27th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of $3.00 per share for the year. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDNGet Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.08 million.

Several other research analysts have also commented on the company. Needham & Company LLC reissued a “buy” rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Royal Bank of Canada boosted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Finally, TD Cowen started coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating for the company. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Viridian Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $35.70.

View Our Latest Research Report on Viridian Therapeutics

Viridian Therapeutics Stock Up 1.1 %

Shares of NASDAQ VRDN opened at $19.43 on Tuesday. Viridian Therapeutics has a 12 month low of $11.40 and a 12 month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -4.51 and a beta of 1.13. The business has a 50-day moving average of $19.42 and a 200-day moving average of $19.40.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRDN. Dimensional Fund Advisors LP grew its stake in shares of Viridian Therapeutics by 968.3% in the second quarter. Dimensional Fund Advisors LP now owns 107,580 shares of the company’s stock worth $1,400,000 after acquiring an additional 97,510 shares during the last quarter. Squarepoint Ops LLC raised its holdings in Viridian Therapeutics by 430.3% in the 2nd quarter. Squarepoint Ops LLC now owns 142,936 shares of the company’s stock worth $1,860,000 after purchasing an additional 115,980 shares during the period. Millennium Management LLC lifted its position in shares of Viridian Therapeutics by 1,014.7% during the 2nd quarter. Millennium Management LLC now owns 228,182 shares of the company’s stock valued at $2,969,000 after buying an additional 207,711 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Viridian Therapeutics by 30.7% during the second quarter. The Manufacturers Life Insurance Company now owns 31,687 shares of the company’s stock valued at $412,000 after purchasing an additional 7,450 shares in the last quarter. Finally, Algert Global LLC boosted its holdings in Viridian Therapeutics by 46.7% in the 2nd quarter. Algert Global LLC now owns 55,493 shares of the company’s stock worth $722,000 after buying an additional 17,673 shares during the period.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

See Also

Earnings History and Estimates for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.